2. Guan W., Ni Z., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–20.https://dx.doi.org/1056/NEJMoa2002032.

3. Inamdar S., Benias P., Liu Y. et al. Prevalence, risk factors, and outcomes of hospitalized patients with coronavirus disease 2019 presenting as acute pancreatitis. Gastroenterology. 2020; 159(6): 2226–28.e2. https://dx.doi.org/10.1053/j.gastro.2020.08.044.

4. Pan L., Mu M., Yang P. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020; 115(5): 766–73. https://dx.doi.org/10.14309/ajg.0000000000000620.

5. Mao R., Qiu Y., He J. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(7): 667–78.https://dx.doi.org/10.1016/S2468-1253(20)30126-6.

6. Cheung K.S., Hung I.F.N., Chan P.P.Y. et al Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. 2020; 159(1): 81–95. https://dx.doi.org/10.1053/j.gastro.2020.03.065.

7. Zhou P., Yang X.L., Wang X.G. et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020.01.22.914952. https://dx.doi.org/10.1101/2020.01.22.914952.

8. Hung I.F., Cheng V.C., Wu A.K. et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004; 10(9): 1550–57. https://dx.doi.org/10.3201/eid1009.040058.

9. Trottein F., Sokol H. Potential causes and consequences of gastrointestinal disorders during a SARS-CoV-2 infection. Cell Rep. 2020; 32(3): 107915. https://dx.doi.org/10.1016/j.celrep.2020.107915.

10. Macfarlane S., Dillon J. Microbial biofilms in the human gastrointestinal tract. Appl Microbiol. 2007; 102(5): 87–96. https://dx.doi.org/10.1111/j.1365-2672.2007.03287.x.

11. Щикота А.М., Погонченкова И.В., Турова Е.А. с соавт. Поражение желудочно-кишечного тракта, печени и поджелудочной железы при COVID-19. Доказательная гастроэнтерология. 2021; 10(1): 30–37.

12. Dioscoridi L. Pancreas and coronavirus disease-2019. Pancreas Open J. 2020; 4(1): 11–23. https://dx.doi.org/10.17140/POJ-4-111.

13. Fan Z., Chen L., Li J. et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020; 18(7): 1561–66. https://dx.doi.org/10.1016/j.cgh.2020.04.002.

14. Patel K.P., Patel P.A., Vunnam R.R. et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020; 128: 104386. https://dx.doi.org/10.1016/j.jcv.2020.104386.

15. Cryan J.F., Dinan T.G. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012; 13(10): 701–12. https://dx.doi.org/10.1038/nrn3346.

16. Martins-Filho P.R., Tavares C.S., Santos V.S. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. Eur J Intern Med. 2020; 76: 97–99. https://dx.doi.org/10.1016/j.ejim.2020.04.043.

17. Liu F., Long X., Zhang B. et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020; 18(9): 2128–30. https://dx.doi.org/10.1016/j.cgh.2020.04.040.

18. Kow C.S., Hasan S.S. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: A meta-analysis. Intern Med. 2021; 289(1): 125–28. https://dx.doi.org/10.1111/joim.13183.

19. Luxenburger H., Sturm L., Biever P. et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: Coincidence or underestimated risk factor. Intern Med. 2021; 289(1): 121–24. https://dx.doi.org/10.1111/joim.13121.

20. Barlass U., Wiliams B., Dhana K. et al. Marked elevation of lipase in COVID-19 disease: A cohort study. Clin Transl Gastroenterol. 2020; 11(7): e00215. https://dx.doi.org/10.14309/ctg.0000000000000215.

21. Muller J., Gro R., Conzelmann C. et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021; 3(2): 149–65. https://dx.doi.org/10.1038/s42255-021-00347-1.

22. Money M.E., Hofmann A.F., Hagey L.R. et al. Treatment of irritable bowel syndrome-diarrhea with pancrealipase or colesevelam and association with steatorrhea. Pancreas. 2009; 38(2): 232–33. https://dx.doi.org/10.1097/MPA.0b013e31817c1b36.

23. Aloysius M., Thatti A., Gupta A. et al. COVID-19 presenting as acute pancreatitis. Pancreatology. 2020; 20(5): 1026–27. https://dx.doi.org/10.1016/j.pan.2020.05.003.

24. Baker S.S. Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with COVID-19. Ther Clin Risk Manag. 2019; 4(5): 1079–84. https://dx.doi.org/10.2147/tcrm.s3123.

25. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420–22. https://dx.doi.org/10.1016/ S2213-2600(20)30076-X.

26. Ивашкин В.Т., Маев И.В., Охлобыстин А.В. с соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; 28(2): 72–100.

27. Ивашкин В.Т., Шептулин А.А., Зольникова О.Ю. с соавт. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2020; 30(3): 7–13.